Compare Amphastar Pharmaceuticals Inc (AMPH) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs iShares Core High Dividend ETF — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while iShares Core High Dividend ETF trades at $27.81. The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | HDV | |
|---|---|---|
Market Cap | $826.08M | — |
Sector | Health | — |
52-Week High | $30.81 | $28.09 |
52-Week Low | $16.87 | $23.63 |
Enterprise Value | $1.22B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
HDV (iShares Core High Dividend ETF) trades at $27.70, up 0.44% with a bullish technical signal from moving averages. The ETF focuses on high-quality dividend stocks with a 3.0% yield and has delivered strong 5-year total returns. Recent news highlights HDV's competitive expense ratio, defensive sector allocation, and lower volatility compared to the S&P 500.
HDV presents a compelling income opportunity with quality screening and defensive positioning, though its 21.56% energy allocation introduces sector-specific volatility. The ETF's low beta of 0.52 provides stability, making it suitable for risk-averse investors seeking dividend income with moderate growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
